clinical trial · NCT07370818
To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
Ovarian CancerJPI-547Bevacizumab
brief summary
This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients
started
Feb 27, 2026
primary completion
Dec 31, 2029
completion
Dec 31, 2031
last updated
Jan 27, 2026
official title
An Open-label, Dose-finding and Randomized Active-controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of JPI-547 With Bevacizumab Maintenance Therapy in Relapsed Ovarian Cancer Patients Previously Treated With PARP Inhibitor Maintenance Therapy and Responding to Last Platinum Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol